Back to search

Article

Optimal immunotherapy regimens for NSCLC patients with KRAS mutations: a systematic review and network meta-analysis

2023-05-02

Abstract excerpt

<h4>Objective: </h4> Patients with KRAS-mutated NSCLC will have a lower survival rate than patients with KRAS gene wild-type, for whom the use of immune checkpoint inhibitors has a significant benefit. We conducted a systematic evaluation and network meta-analysis to find the best treatment option for such patients with ICIs by comparing the efficacy of immune checkpoint inhibitors (PD-1/PD-L1 inhibitors as well a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d9c56232-f3a8-5b64-8de1-344b33e50bde
DOI
10.21203/rs.3.rs-2794257/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Optimal immunotherapy regimens for NSCLC patients with KRAS mutations: a systematic review and network meta-analysisDOI 10.21203/rs.3.rs-2794257/v1
Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with KRAS mutations: A network meta-analysis.Semantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.Semantic proximity
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.Semantic proximity
Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity
KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence.Semantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity
Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small-cell lung cancer: a systematic review and network meta-analysis.Semantic proximity
Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.Semantic proximity
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity
Select a neighboring publication to make it the new centre.